News
CUE
1.890
+2.72%
0.050
Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline
NASDAQ · 1d ago
Weekly Report: what happened at CUE last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at CUE last week (0311-0315)?
Weekly Report · 03/18 11:04
Cue Biopharma Inc <CUE.OQ> expected to post a loss of 28 cents a share - Earnings Preview
Cue Biopharma Inc expected to post a loss of 28 cents a share. The company is expected to report a 937.7% increase in quarterly revenue to $1.567 million. Wall Street's median 12-month price target for the company is $8.00.
Reuters · 03/15 21:08
Jefferies starts cue at buy, cites partnering potential
Healthcare Jefferies starts cue at buy, cites partnering potential. Cue Biopharma, Inc. (CUE) Stock. Jefferies has initiated coverage of Cue with a buy rating. The company’s autoimmune platform could potentially attract partner interest, Jefferies says.
Seeking Alpha · 03/13 18:55
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Clover Health Investments, Corp. Shares jumped 11.2% to $0.8537 on Wednesday. The company reported better-than-expected fourth-quarter revenue results. Gaxos.ai shares jumped 128.9% after the company acquired rights to use certain AI-enabled technology from Ultiself. Veritone, Inc. And The Beauty Health Company also gained.
Benzinga · 03/13 17:18
Solid Biosciences, Cue Biopharma, Annexon among healthcare movers
Solid Biosciences, Cue Biopharma, Annexon among healthcare movers. S&P 500 Health Care Sector +0.01% to 1710.78. Pharmaceuticals, Biotechnology & Life Science contributes 0.14% to index is -0.12%.
Seeking Alpha · 03/13 14:00
Cue Biopharma Price Target Announced at $6.00/Share by Jefferies
Dow Jones · 03/13 13:12
Cue Biopharma Initiated at Buy by Jefferies
Dow Jones · 03/13 13:12
Jefferies Initiates Coverage On Cue Biopharma with Buy Rating, Announces Price Target of $6
Benzinga · 03/13 13:02
Analysts’ Top Healthcare Picks: Cooper Co (COO), Regeneron (REGN)
TipRanks · 03/13 09:01
CytomX Therapeutics (CTMX) Lags Q4 Earnings Estimates
NASDAQ · 03/11 21:20
Weekly Report: what happened at CUE last week (0304-0308)?
Weekly Report · 03/11 11:01
Weekly Report: what happened at CUE last week (0226-0301)?
Weekly Report · 03/04 11:04
Strength Seen in Precision BioSciences (DTIL): Can Its 20.4% Jump Turn into More Strength?
NASDAQ · 02/27 09:25
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Intellia Therapeutics (NTLA) and Cue Biopharma (CUE)
TipRanks · 02/26 13:10
Weekly Report: what happened at CUE last week (0219-0223)?
Weekly Report · 02/26 11:16
Cue Biopharma (CUE) Gets a Buy from Piper Sandler
TipRanks · 02/20 12:45
Weekly Report: what happened at CUE last week (0212-0216)?
Weekly Report · 02/19 11:18
Weekly Report: what happened at CUE last week (0205-0209)?
Weekly Report · 02/12 11:08
More
Webull provides a variety of real-time CUE stock news. You can receive the latest news about Cue Biopharma Inc through multiple platforms. This information may help you make smarter investment decisions.
About CUE
Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a novel class of injectable biologics designed to selectively engage and modulate tumor-specific T cells within the body to treat a broad range of cancers, chronic infectious diseases, and autoimmune diseases. The Company’s proprietary Immuno-STAT (Selective Targeting and Alteration of T Cells) platform harnesses the patient’s intrinsic immune repertoire to fully exploit its potential to fight cancer and restore health while avoiding the deleterious side effects of broad immune activation. The Company’s lead product candidate from the CUE-100 series, CUE-101, is a fusion protein biologic designed to target and activate antigen-specific T cells to fight HPV-driven cancers. Its second drug product candidate, CUE-102, targets Wilms’ Tumor 1 protein (WT-1), an oncofetal antigen. It is also developing CUE-103 and its Neo-STAT and RDI-STAT programs outside of oncology.